Data as of Jul 21
| -0.18 / -2.89%|
The 8 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 11.25, with a high estimate of 26.00 and a low estimate of 7.00. The median estimate represents a +85.95% increase from the last price of 6.05.
The current consensus among 9 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.